IGC Pharma Inc. announced the issuance of U.S. Patent No. 12,491,200 covering its novel microdose-based cannabinoid treatment for stuttering and Tourette's Syndrome. The patent protects methods utilizing ultra-low doses of THC, alone or in combination with CBD or other agents, to modulate neural circuits involved in vocal disruptions, tics, and involuntary motor symptoms. This development expands the company's intellectual property portfolio beyond Alzheimer's disease and supports its strategy to advance targeted neurological therapies using cannabinoid-based approaches.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IGC Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1119358) on December 19, 2025, and is solely responsible for the information contained therein.